**[372] KAHR’S CURRENT AND FUTURE DUAL SIGNALING PROTEINS (DSP) DRUG PLATFORMS**

**Noam Shani1, 1 Kahr Medical LTD**

**KAHR’s current and future Dual Signaling Proteins (DSP) drug platforms**

**Investment Rational**
KAHR Medical is an Israeli biotech startup company pioneering the development of ‘Dual Signaling Proteins' (DSP); fusion proteins with two functional ends, for the treatment of cancer and autoimmune diseases. To date, KAHR have raised $30 million, mainly from Israeli, South Korean and Swedish investment funds.

* **Business Strategy**
KAHR's long-term vision is to become a fully integrated pharmaceutical company, developing and bringing to market its own DSP-based products. In the short-term, KAHR will partner with strategic partners that will lead clinical development to the market. Revenues from initial out-licensing deals will fund further development of additional DSP drug candidates to more advanced stages.
* **Core Technology**
‘Dual Signaling Proteins' (DSP) are bi-functional proteins that are formed by fusing the extracellular domain of a Type-I membrane protein to the extracellular domain of a Type-II membrane protein (e.g., TNF superfamily ligands), forming one protein with two functional sides. The DSP technology is divided into two proprietary platforms; DSP-Hexamers and DSP-Clusters, both representing hundreds of drug candidates.

**Product Profile/Pipeline**
KAHR has two active drug-development programs which represent proof-of–concept for its two proprietary platforms -

KAHR-102 (CTLA4-FasL) is the company’s lead product, and represents the DSP-Hexamer technology platform. KAHR-102 has completed toxicology studies and has regulatory approval to initiate Phase-I/II in lymphoma patients in Israel.

KAHR-101 (Fn14-TRAIL), represents the DSP-Clusters technology platform. KAHR-101 completed Proof-Of-Concept in solid tumor and autoimmune animal disease models and is poised for production-upscaling and toxicology

* **What's Next?**
KAHR is currently focused on bringing its two lead product, KAHR-101 and KAHR-102, to the clinic. KAHR’s future product pipeline is being constructed by selecting new DSP drug candidates and demonstrating cancer immunotherapy proof-of-concept.